论文部分内容阅读
噻氯匹定(ticlopidine,坻克力得、力抗栓)是一种血小板功能抑制剂.近年来随着对脑卒中治疗方法和药物的研究,对人体凝血机制以及抗凝机理的研究也日益增加,新型抗凝血药也在不断地被开发应用.噻氯匹定是一种比较新的抑制血小板功能的药物.临床用药表明,该药可明显延长凝血时间,发挥抗凝作用.但噻氯匹定对脑卒中患者血浆纤维蛋白原的影响尚未见国内有报道.我们通过41例脑卒中患者服用该药前后各项实验指标的观察,探讨噻氯匹定的抗凝机制.l 材料与方法1.1 仪器 血液凝固分析装置(日本东亚医用电子株式会社制造);Cell-DYN-1400(美国贝克曼公司制造).1.2 药品 盐酸噻氯匹定(法国产,批号为0295 067,剂量为0.25mg).
Ticlopidine (ticlopidine) is a platelet function inhibitor.In recent years, with the study of stroke treatment and drug research on human coagulation mechanism and anticoagulant mechanism is also increasingly Increase, new anticoagulants are also being continuously developed and applied.Ticrotiline is a relatively new drug that inhibits platelet function.Clinical use of drugs shows that the drug can significantly prolong the clotting time, to play a role in anticoagulation, but thiophene Clopidogrel on stroke in patients with plasma fibrinogen impact has not been reported in the country.We adopted 41 cases of stroke patients taking the drug before and after the observation of the experimental indicators to explore the anticoagulant mechanism of ticlopidine.l material and Method 1.1 Apparatus Blood coagulation analyzer (manufactured by Toa Tohmatsu Co., Ltd.) Cell-DYN-1400 (manufactured by Beckman Co., U.S.A.) 1.2 Ticlopidine Hydrochloride (French, lot number 0295 067, ).